
    
      Participants who meet all the study entry criteria will be randomly allocated to 2 possible
      sequences of the 2 treatment regimens over the course of 2 menstrual cycles.

      In treatment sequence 1, participants will receive etoricoxib 120 mg daily in menstrual cycle
      1, and ibuprofen up to 2400 mg/daily in menstrual cycle 2. In treatment sequence 2,
      participants will receive ibuprofen up to 2400 mg/daily in menstrual cycle 1 and etoricoxib
      120 mg daily in menstrual cycle 2.
    
  